maritide - Search News

Amgen, obesity and MariTide

Amgen starts two critical late-stage trials for weight loss drug MariTide

MariTide is a monthly injection that investors hope could compete against existing weight loss drugs from Novo Nordisk and Eli Lilly.

FierceBiotech · 9h

Amgen enters Maritime, launching 2 late-stage obesity trials for MariTide

Amgen’s most advanced obesity asset MariTide is entering Maritime—that is, a phase 3 program that includes two freshly launched trials. | Amgen’s most advanced obesity asset MariTide is entering Maritime—that is,

Seeking Alpha on MSN · 11h

Amgen begins late-stage trials for obesity therapy

Amgen (NASDAQ:AMGN) has announced the beginning of two Phase 3 studies for its weight loss candidate MariTide as the company aims to take a slice of a burgeoning obesity drug market dominated by Eli Lilly (LLY) and Novo Nordisk (NVO).

Business Insider · 9h

Amgen (NASDAQ:AMGN) Enters Late-Stage Testing on Weight Loss Drug

We know that weight loss drugs have been big winners for the companies that produce them. And now, biotech stock Amgen (AMGN) looks to get in

Bloomberg L.P. · 12h

Amgen Starts Final-Stage Studies of Its Monthly Obesity Drug

Amgen Inc. launched two final-stage studies of its monthly obesity treatment, a closely watched drug that would compete with blockbuster weight-loss medicines from Eli Lilly & Co. and Novo Nordisk A/S.

This Could Be the Best GLP-1 Stock to Buy in 2025

That's a potential steal. The average stock in the Health Care Select Sector SPDR Fund trades at a multiple of just under 18 ...

Amgen Stock: Why I Still Rate It A 'Buy'

Amgen released financial results for the 4th quarter of 2024. Check out why I continue to cover AMGN stock with a 'Buy' ...

13don MSN

From pills to new uses, here's what Eli Lilly's top scientist sees as the future of weight loss drugs

Eli Lilly Chief Scientific Officer Dan Skovronsky spoke to CNBC about obesity pills and more on the future of weight loss.

Reuters1mon

Amgen profits rise, next MariTide studies start by mid-year

MariTide Phase 3 studies to begin in first half of year FDA places hold on AMG 513 obesity drug trial Amgen's Q4 earnings beat estimates, revenue up 11% Feb 4 (Reuters) - Amgen (AMGN.O), opens new ...

8hon MSN

Amgen just got one step closer to bringing its Ozempic competitor to market

Amgen (AMGN) is getting closer to challenging the weight-loss drug duopoly of Novo Nordisk (NVO), the maker of Ozempic and Wegovy, and Eli Lilly (LLY), which produces Zepbound.

Some results have been hidden because they may be inaccessible to you

Show inaccessible results